Delta Financial Advisors LLC Has $340,000 Stake in AbbVie Inc. (NYSE:ABBV)

Posted by Ethan Ryder on Apr 18th, 2024

Delta Financial Advisors LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV – potlac na tricka
adidas deerupt panske zelene
faraway42.com
kuffert tilbud
damske teplaky
???? ????? ?????? ????? ??????
tri?ká s potla?ou
cindyrodriguezcopywriting.com
cindyrodriguezcopywriting.com
make up astor skin match
adidas deerupt panske zelene
tri?ká s potla?ou
kuffert tilbud
make up astor skin match
christianslouboutins.com

RegistrationCode=TickerHyperlink&Prefix=NYSE&Symbol=ABBV”>Free Report) by 20.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,197 shares of the company’s stock after selling 550 shares during the period. Delta Financial Advisors LLC’s holdings in AbbVie were worth $340,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ABBV. Hibernia Wealth Partners LLC acquired a new position in shares of AbbVie during the third quarter worth approximately $36,000. PCA Investment Advisory Services Inc. acquired a new position in shares of AbbVie during the second quarter worth approximately $38,000. True Wealth Design LLC acquired a new position in shares of AbbVie during the fourth quarter worth approximately $39,000. Blue Bell Private Wealth Management LLC raised its stake in shares of AbbVie by 39.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 286 shares of the company’s stock worth $43,000 after buying an additional 81 shares during the last quarter. Finally, Horrell Capital Management Inc. bought a new stake in shares of AbbVie during the third quarter worth approximately $45,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 1.0 %

Shares of AbbVie stock traded up $1.58 on Thursday, hitting $165.83. The company had a trading volume of 1,881,170 shares, compared to its average volume of 5,601,653. The firm has a market capitalization of $293.63 billion, a P/E ratio of 60.89, a P/E/G ratio of 2.09 and a beta of 0.58. AbbVie Inc. has a twelve month low of $130.96 and a twelve month high of $182.89. The company has a debt-to-equity ratio of 5.02, a current ratio of 0.87 and a quick ratio of 0.76. The stock has a 50-day moving average of $175.79 and a 200-day moving average of $159.94.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.03. The company had revenue of $14.30 billion during the quarter, compared to analysts’ expectations of $14.02 billion. AbbVie had a net margin of 8.95% and a return on equity of 162.28%. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.60 earnings per share. Research analysts predict that AbbVie Inc. will post 11.17 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $1.55 per share. This represents a $6.20 annualized dividend and a yield of 3.74%. The ex-dividend date of this dividend is Friday, April 12th. AbbVie’s payout ratio is 227.11%.

Insider Buying and Selling

In related news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total transaction of $9,184,047.70. Following the completion of the transaction, the executive vice president now owns 243,944 shares in the company, valued at $42,375,512.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other AbbVie news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total value of $9,184,047.70. Following the completion of the sale, the executive vice president now owns 243,944 shares in the company, valued at $42,375,512.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Nicholas Donoghoe sold 21,082 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the completion of the sale, the executive vice president now owns 55,903 shares of the company’s stock, valued at approximately $9,855,698.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 383,324 shares of company stock worth $67,780,003. 0.25% of the stock is owned by insiders.

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. Guggenheim boosted their price target on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Truist Financial boosted their price target on shares of AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. BMO Capital Markets boosted their price target on shares of AbbVie from $187.00 to $195.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Raymond James boosted their price target on shares of AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Finally, Barclays boosted their price target on shares of AbbVie from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 27th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $177.43.

Get Our Latest Report on ABBV

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.